Middle East and Africa Biopharmaceuticals Contract Manufacturing Market- Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
Description
Market Overview
The Middle East and Africa biopharmaceuticals contract manufacturing market is anticipated to grow from USD 686.08 million in 2023 to approximately USD 1,981.91 million by 2032, registering a compound annual growth rate (CAGR) of 24.95%.
This rapid growth is fueled by rising demand for cost-efficient, high-quality manufacturing solutions and an increasing tendency among pharmaceutical firms to outsource due to the complexity of modern drug formulations. Government-led initiatives aimed at strengthening healthcare infrastructure and attracting foreign investment further support market expansion. The prevalence of chronic illnesses and growing demand for advanced biologic treatments are encouraging pharmaceutical companies to partner with contract manufacturing organizations (CMOs) for their specialized capabilities. Emerging trends include the integration of innovative technologies such as single-use bioreactors and continuous processing systems, both of which optimize efficiency and reduce manufacturing costs. The increasing focus on biosimilars and personalized medicine is also reshaping the landscape, as contract manufacturers offer flexible, scalable models to meet evolving market requirements. With a rapidly evolving healthcare ecosystem, the Middle East and Africa are poised for substantial growth in biopharmaceutical contract manufacturing services.
Market Drivers
Rising Demand for Biologics and Biosimilars
The escalating need for biologics and biosimilars is a key driver of growth in the Middle East and Africa biopharmaceuticals contract manufacturing market. As global demand shifts toward biologic therapies targeting chronic and complex diseases, companies across the region are seeking efficient and cost-effective production alternatives. According to a Middle East Health Authority survey, pharmaceutical firms are increasingly partnering with CMOs to capitalize on their expertise in biologics, enabling quicker market entry while maintaining quality and reducing costs. Moreover, the growth of biosimilars presents a viable alternative to high-cost biologics, further reinforcing the role of contract manufacturers in facilitating affordable therapeutic solutions.
Market Challenges Analysis
Regulatory Complexity and Compliance Barriers
Regulatory hurdles remain a major challenge for the biopharmaceuticals contract manufacturing sector in the Middle East and Africa. The region's fragmented regulatory environment—varying from country to country—poses obstacles for CMOs aiming to expand or enter new markets. The Middle East Health Authority notes that strict adherence to good manufacturing practices (GMP), quality standards, and country-specific requirements is essential for product integrity. However, inconsistent regulation enforcement, lack of regional harmonization, and prolonged approval procedures often result in delays and increased operational costs. Successfully overcoming these regulatory barriers demands significant resource allocation and tailored compliance strategies for each market, especially for organizations looking to scale operations across the region.
Segments
By Source:
Mammalian
Non-mammalian
By Service:
Process Development
Downstream
Upstream
Fill & Finish Operations
Analytical & QC Studies
Packaging & Labelling
Others
By Drug Type:
Biologics:
Monoclonal Antibodies (mAbs)
Recombinant Proteins
Vaccines
Antisense, RNAi, & Molecular Therapy
Others
Biosimilars
By Type:
Drug Substance
Finished Drug Product
By Scale of Operation:
Clinical
Commercial
By Therapeutic Area:
Oncology
Autoimmune Diseases
Cardiovascular Diseases
Infectious Diseases
Others
By Geography:
UAE
KSA
Israel
Turkey
Iran
Egypt
Nigeria
Algeria
Key Player Analysis
Boehringer Ingelheim GmbH
Lonza
JRS PHARMA
AGC Biologics
Samsung Biologics
Thermo Fisher Scientific, Inc.
ADMA Biologics, Inc.
Catalent, Inc.
Cambrex Corporation
Pfizer Inc.
Siegfried Holding AG
Ask ChatGPT
The Middle East and Africa biopharmaceuticals contract manufacturing market is anticipated to grow from USD 686.08 million in 2023 to approximately USD 1,981.91 million by 2032, registering a compound annual growth rate (CAGR) of 24.95%.
This rapid growth is fueled by rising demand for cost-efficient, high-quality manufacturing solutions and an increasing tendency among pharmaceutical firms to outsource due to the complexity of modern drug formulations. Government-led initiatives aimed at strengthening healthcare infrastructure and attracting foreign investment further support market expansion. The prevalence of chronic illnesses and growing demand for advanced biologic treatments are encouraging pharmaceutical companies to partner with contract manufacturing organizations (CMOs) for their specialized capabilities. Emerging trends include the integration of innovative technologies such as single-use bioreactors and continuous processing systems, both of which optimize efficiency and reduce manufacturing costs. The increasing focus on biosimilars and personalized medicine is also reshaping the landscape, as contract manufacturers offer flexible, scalable models to meet evolving market requirements. With a rapidly evolving healthcare ecosystem, the Middle East and Africa are poised for substantial growth in biopharmaceutical contract manufacturing services.
Market Drivers
Rising Demand for Biologics and Biosimilars
The escalating need for biologics and biosimilars is a key driver of growth in the Middle East and Africa biopharmaceuticals contract manufacturing market. As global demand shifts toward biologic therapies targeting chronic and complex diseases, companies across the region are seeking efficient and cost-effective production alternatives. According to a Middle East Health Authority survey, pharmaceutical firms are increasingly partnering with CMOs to capitalize on their expertise in biologics, enabling quicker market entry while maintaining quality and reducing costs. Moreover, the growth of biosimilars presents a viable alternative to high-cost biologics, further reinforcing the role of contract manufacturers in facilitating affordable therapeutic solutions.
Market Challenges Analysis
Regulatory Complexity and Compliance Barriers
Regulatory hurdles remain a major challenge for the biopharmaceuticals contract manufacturing sector in the Middle East and Africa. The region's fragmented regulatory environment—varying from country to country—poses obstacles for CMOs aiming to expand or enter new markets. The Middle East Health Authority notes that strict adherence to good manufacturing practices (GMP), quality standards, and country-specific requirements is essential for product integrity. However, inconsistent regulation enforcement, lack of regional harmonization, and prolonged approval procedures often result in delays and increased operational costs. Successfully overcoming these regulatory barriers demands significant resource allocation and tailored compliance strategies for each market, especially for organizations looking to scale operations across the region.
Segments
By Source:
Mammalian
Non-mammalian
By Service:
Process Development
Downstream
Upstream
Fill & Finish Operations
Analytical & QC Studies
Packaging & Labelling
Others
By Drug Type:
Biologics:
Monoclonal Antibodies (mAbs)
Recombinant Proteins
Vaccines
Antisense, RNAi, & Molecular Therapy
Others
Biosimilars
By Type:
Drug Substance
Finished Drug Product
By Scale of Operation:
Clinical
Commercial
By Therapeutic Area:
Oncology
Autoimmune Diseases
Cardiovascular Diseases
Infectious Diseases
Others
By Geography:
UAE
KSA
Israel
Turkey
Iran
Egypt
Nigeria
Algeria
Key Player Analysis
Boehringer Ingelheim GmbH
Lonza
JRS PHARMA
AGC Biologics
Samsung Biologics
Thermo Fisher Scientific, Inc.
ADMA Biologics, Inc.
Catalent, Inc.
Cambrex Corporation
Pfizer Inc.
Siegfried Holding AG
Ask ChatGPT
Table of Contents
196 Pages
- CHAPTER NO. 1 : INTRODUCTION
- 1.1.1. Report Description
- Purpose of the Report
- USP & Key Offerings
- 1.1.2. Key Benefits for Stakeholders
- 1.1.3. Target Audience
- 1.1.4. Report Scope
- CHAPTER NO. 2 : EXECUTIVE SUMMARY
- 2.1. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Snapshot
- 2.1.1. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market, 2018 - 2032 (USD Million)
- CHAPTER NO. 3 : Middle East and Africa Biopharmaceuticals Contract Manufacturing Market – INDUSTRY ANALYSIS
- 3.1. Introduction
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Market Opportunities
- 3.5. Porter’s Five Forces Analysis
- CHAPTER NO. 4 : ANALYSIS COMPETITIVE LANDSCAPE
- 4.1. Company Market Share Analysis – 2023
- 4.2. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Company Revenue Market Share, 2023
- 4.3. Company Assessment Metrics, 2023
- 4.4. Start-ups / SMEs Assessment Metrics, 2023
- 4.5. Strategic Developments
- 4.6. Key Players Product Matrix
- CHAPTER NO. 5 : PESTEL & ADJACENT MARKET ANALYSIS
- CHAPTER NO. 6 : Middle East and Africa Biopharmaceuticals Contract Manufacturing Market – BY Based on Source: ANALYSIS
- CHAPTER NO. 7 : Middle East and Africa Biopharmaceuticals Contract Manufacturing Market – BY Based on Service: ANALYSIS
- CHAPTER NO. 8 : Middle East and Africa Biopharmaceuticals Contract Manufacturing Market – BY Based on Drug Type: ANALYSIS
- CHAPTER NO. 9 : Middle East and Africa Biopharmaceuticals Contract Manufacturing Market – BY Based on Type: ANALYSIS
- CHAPTER NO. 10 : Middle East and Africa Biopharmaceuticals Contract Manufacturing Market – BY Based on Scale of Operation: ANALYSIS
- CHAPTER NO. 11 : Middle East and Africa Biopharmaceuticals Contract Manufacturing Market – BY Based on Therapeutic Area: ANALYSIS
- CHAPTER NO. 12 : Middle East and Africa Biopharmaceuticals Contract Manufacturing Market – BY Based on the Geography: ANALYSIS
- CHAPTER NO. 13 : COMPANY PROFILES
- 13.1. Boehringer Ingelheim GmbH
- 13.2. Lonza
- 13.3. JRS PHARMA
- 13.4. AGC Biologics
- 13.5. Samsung Biologics
- 13.6. Thermo Fisher Scientific, Inc.
- 13.7. ADMA Biologics, Inc.
- 13.8. Catalent, Inc.
- 13.9. Cambrex Corporation
- 13.10. Pfizer Inc.
- 13.11. Siegfried Holding AG
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
